Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinsons disease and other Lewy body disorders

Immunotherapy

Volumn 6, Issue 2, 2014, Pages 141-153

  Lindström, Veronica ^a   Ihse, Elisabet ^a   Fagerqvist, Therese ^a   Bergström, Joakim ^a   Nordström, Eva ^b   Möller, Christer ^b   Lannfelt, Lars ^a   Ingelsson, Martin ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BioArctic Neuroscience   (Sweden)

Author keywords

synuclein; antibody; immunization; immunotherapy; Parkinsons disease

Indexed keywords

ALPHA-SYNUCLEIN; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; LEWY BODIES; LEWY BODY DISEASE; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PARKINSON DISEASE; UNFOLDED PROTEIN RESPONSE;

EID: 84893876192     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.162     Document Type: Review

References (93)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 373(9680), 2055-2066 (2009).
2. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72(13), 1121-1126 (2009).
3. Riedel O, Klotsche J, Spottke A et al. Frequency of dementia, depression other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J. Neurol. 257(7), 1073-1082 (2010).
4. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23(6), 837-844 (2008).
5. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12), 1863-1872 (2005). (Pubitemid 43970103)
6. Hansen L, Salmon D, Galasko D et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 40(1), 1-8 (1990). (Pubitemid 20032882)
7. Jecmenica-Lukic M, Poewe W, Tolosa E. Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol. 11(4), 361-368 (2012).
8. Eller M, Williams DR. Alpha-synuclein in Parkinson disease and other neurodegenerative disorders. Clin. Chem. Lab. Med. 49(3), 403-408 (2011).
9. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10(3), 378-384 (2000). (Pubitemid 30431290)
10. Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 9(4), 721-732 (1999). (Pubitemid 29470964)
11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 388(6645), 839-840 (1997).
12. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta NeuroPathol. 119(6), 703-713 (2010).
13. Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. Mov. Disord. 28(2), 237-240 (2013).
14. Ballard C, Aarsland D, Francis P, Corbett A. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features pharmacological management. Drugs Aging 30(8), 603-611 (2013).
15. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276(14), 10737-10744 (2001). (Pubitemid 38089246)
16. Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging FASEB J. 20(12), 2050-2057 (2006). (Pubitemid 44953904)
17. Harding AJ and Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta NeuroPathol. 102(4), 355-363 (2001). (Pubitemid 32894706)
18. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279(6), 4625-4631 (2004). (Pubitemid 38199054)
19. Kramer ML and Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27(6), 1405-1410 (2007).
20. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27(34), 9220-9232 (2007). (Pubitemid 47312071)
21. Outeiro TF, Putcha P, Tetzlaff JE et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE 3(4), e1867 (2008).
22. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 29(11), 1690-1701 (2008).
23. Karpinar DP, Balija MB, Kugler S et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28(20), 3256-3268 (2009).
24. Kiely AP, Asi YT, Kara E et al. Alpha-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta NeuroPathol. 125(5), 753-769 (2013).
25. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M et al. Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. (2013).
26. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18(R1), R48-R59 (2009).
27. Farrer M, Kachergus J, Forno L et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55(2), 174-179 (2004). (Pubitemid 38166993)
28. Chartier-Harlin MC, Kachergus J, Roumier C et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364(9440), 1167-1169 (2004). (Pubitemid 39296604)
29. Ibanez P, Bonnet AM, Debarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364(9440), 1169-1171 (2004). (Pubitemid 39296605)
30. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97(2), 571-576 (2000). (Pubitemid 30070350)
31. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37(4), 583-595 (2003). (Pubitemid 36262981)
32. Paleologou KE, Kragh CL, Mann DM et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132(Pt 4), 1093-1101 (2009).
33. Tokuda T, Salem SA, Allsop D et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162-166 (2006). (Pubitemid 44331776)
34. Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T et al. Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 32(10), 3306-3320 (2012).
35. Zhang W, Wang T, Pei Z et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19(6), 533-542 (2005). (Pubitemid 40471244)
36. Wilms H, Rosenstiel P, Romero-Ramos M et al. Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int. J. Immunopathol. Pharmacol. 22(4), 897-909 (2009).
37. Diogenes MJ, Dias RB, Rombo DM et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J. Neurosci. 32(34), 11750-11762 (2012).
38. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 124(2), 153-172 (2012).
39. Payne KK, Toor AA, Wang XY, Manjili MH. Immunotherapy of cancer: reprogramming tumor-immune crosstalk. Clin. Dev. Immunol. 2012, 760965 (2012).
40. Magdelaine-Beuzelin C, Pinault C, Paintaud G, Watier H. Therapeutic antibodies in ophthalmology: old is new again. MAbs 2(2), 176-180 (2011).
41. Lems WF, den Heijer M. Established and forthcoming drugs for the treatment of osteoporosis. Neth. J. Med. 71(4), 188-193 (2013).
42. Van De Velde AL, Anguille S, Berneman ZN. Immunotherapy in leukaemia. Acta Clin. Belg. 67(6), 399-402 (2013).
43. Rudick R, Polman C, Clifford D, Miller D Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 70(2), 172-182 (2013).
44. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740), 173-177 (1999). (Pubitemid 29327547)
45. Gilman S, Koller M, Black RS et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9), 1553-1562 (2005). (Pubitemid 40617691)
46. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14(1), 11-20 (2004). (Pubitemid 38200585)
47. Kokjohn TA, Roher AE. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol. Disord. Drug Targets 8(2), 88-97 (2009).
48. Vellas B, Black R, Thal LJ et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6(2), 144-151 (2009).
49. Kotilinek LA, Bacskai B, Westerman M et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22(15), 6331-6335 (2002). (Pubitemid 35386387)
50. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8), 916-919 (2000). (Pubitemid 30644751)
51. Dodart JC, Bales KR, Gannon KS et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5(5), 452-457 (2002). (Pubitemid 34454251)
52. Mohajeri MH, Gaugler MN, Martinez J et al. Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. Neurodegener. Dis. 1(4-5), 160-167 (2004). (Pubitemid 39551792)
53. Salloway S, Sperling R, Gilman S, Fox NC et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24), 2061-2070 (2009).
54. Siemers ER, Friedrich S, Dean RA et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol. 33(2), 67-73 (2010).
55. Lord A, Gumucio A, Englund H et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 36(3), 425-434 (2009).
56. Sehlin D, Hedlund M, Lord A et al. Heavy-chain complementarity- determining regions determine conformation selectivity of anti-abeta antibodies. Neurodegener. Dis. 8(3), 117-123 (2011).
57. Masliah E, Rockenstein E, Adame A et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6), 857-868 (2005). (Pubitemid 40805347)
58. Masliah E, Rockenstein E, Veinbergs I et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456), 1265-1269 (2000). (Pubitemid 30112148)
59. Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. Alpha-synuclein vaccination prevents the accumulation of Parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J. Neuropathol. Exp. Neurol. 72(7), 624-645 (2013).
60. Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson's disease. Parkinsonism Relat. Disord. 18(Suppl. 1), S11-S13 (2012).
61. Masliah E, Rockenstein E, Mante M et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6(4), e19338 (2011).
62. Dufty BM, Warner LR, Hou ST et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J. Pathol. 170(5), 1725-1738 (2007). (Pubitemid 47339316)
63. Moraitou M, Hadjigeorgiou G, Monopolis I et al. Beta-glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Mol. Genet. Metab. 104(1-2), 149-152 (2011).
64. El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20(3), 419-425 (2006). (Pubitemid 44933318)
65. El-Agnaf OM, Salem SA, Paleologou KE et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17(13), 1945-1947 (2003).
66. Foulds PG, Mitchell JD, Parker A et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25(12), 4127-4137 (2011).
67. Desplats P, Lee HJ, Bae EJ et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106(31), 13010-13015 (2009).
68. Hansen C, Angot E, Bergstrom AL et al. Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121(2), 715-725 (2011).
69. Lee HJ, Suk JE, Patrick C et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285(12), 9262-9272 (2010).
70. Danzer KM, Kranich LR, Ruf WP et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42 (2012).
71. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 113(5), 1263-1274 (2010).
72. Gousset K, Schiff E, Langevin C et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 11(3), 328-336 (2009).
73. Emmanouilidou E, Elenis D, Papasilekas T et al. Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS ONE 6(7), e22225 (2011).
74. Bae EJ, Lee HJ, Rockenstein E et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32(39), 13454-13469 (2012).
75. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23(12), 2223-2226 (2002). (Pubitemid 36092057)
76. Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 10(3), 459-472 (2013).
77. Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol Biol. 368(4), 1132-1144 (2007). (Pubitemid 46574670)
78. Fagerqvist T, Lindstrom V, Nordstrom E et al. Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and transgenic mice expressing the disease-causing A30P mutation. J. Neurochem. 126(1), 131-144 (2013).
79. Nasstrom T, Goncalves S, Sahlin C et al. Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS ONE 6(10), e27230 (2011).
80. Freichel C, Neumann M, Ballard T et al. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol. Aging 28(9), 1421-1435 (2007). (Pubitemid 47081234)
81. Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 10(6), 1023-1031 (2004). (Pubitemid 39625246)
82. Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 377(1), 136-147 (2008).
83. Rock RB, Gekker G, Hu S et al. Role of microglia in central nervous system infections. Clin. Microbiol. Rev. 17(4), table of contents 942-964 (2004). (Pubitemid 39372525)
84. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 32(5), 593-604 (2010).
85. Laurie C, Reynolds A, Coskun O, Bowman E, Gendelman HE, Mosley RL. CD4+ T cells from copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 183(1-2), 60-68 (2007). (Pubitemid 46204910)
86. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 82(5), 1083-1094 (2007). (Pubitemid 350133504)
87. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J. Immunol. 184(5), 2261-2271 (2010).
88. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98(15), 8850-8855 (2001). (Pubitemid 32678116)
89. Besong-Agbo D, Wolf E, Jessen F et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80(2), 169-175 (2012).
90. Gruden MA, Sewell RD, Yanamandra K et al. Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J. Neuroimmunol. 233(1-2), 221-227 (2011).
91. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA. Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 6(4), e18513 (2011).
92. Papachroni KK, Ninkina N, Papapanagiotou A et al. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J. Neurochem. 101(3), 749-756 (2007). (Pubitemid 46633311)
93. Smith LM, Schiess MC, Coffey MP, Klaver AC Loeffler DA. Alpha-synuclein and anti-alpha-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS ONE 7(12), e52285 (2012).